MISSION VIEJO, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) — MYnd Analytics, Inc. (“MYnd”) (OTCQB:MYAN), which provides a unique set of reference data and analytic tools for clinicians to assist in determining the right therapeutic medication for individuals with mental health disorders, announced today the change of its OTCQB trading symbol from “CNSO” to “MYAN.” The trading symbol change is effective as of today.
“The new trading symbol, which is more closely aligned with the MYnd Analytics name, is intended to strengthen the MYnd brand and increase its profile within the investment community,” stated George Carpenter, President and CEO of MYnd Analytics. Analysts have identified predictive analytics for medicine as one of the hottest investment markets in healthcare, particularly, healthcare startups using advanced machine learning algorithms. The predictive analytics market which is geared to improve treatment response is projected to become a $4 billion market by 2020.
Effective today, all information, including stock trading, SEC filings, and market data related to MYnd will be reported under the new ticker symbol, “MYAN.” The CUSIP for company’s common stock will remain 62857N202.
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, as well as those risks and uncertainties set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
CONTACT: Media Contact: Paul Buck Chief Financial Officer pbuck@MYndAnalytics.com